CardioVax LLC has a total of 24 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2002. It filed its patents most often in EPO (European Patent Office), United States and Brazil. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are AFFIRIS AG, RETINAL SOLUTIONS LLC and ALBA THERAPEUTICS CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | United States | 6 | |
#3 | Brazil | 3 | |
#4 | Australia | 2 | |
#5 | China | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Canada | 1 | |
#8 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Enzymes | |
#5 | Analysing materials | |
#6 | Climate change adaptation technologies | |
#7 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Nilsson Jan | 15 |
#2 | Shah Prediman K | 7 |
#3 | Hansson Göran K | 4 |
#4 | Ruiz Stacey | 3 |
#5 | Holmgren Jan | 3 |
#6 | Hermansson Andreas | 3 |
#7 | Carvlin Mark | 2 |
#8 | Duner Claes Pontus | 2 |
#9 | Hansson Goran K | 2 |
#10 | Hansson Goran | 2 |
Publication | Filing date | Title |
---|---|---|
WO2018187746A1 | Osteopontin and thrombin-cleaved fragment thereof and their use in atherosclerosis prevention, inflammation reduction and improving plaque stability | |
WO2017210360A1 | Methods for diagnosing and treating systemic lupus erythematosus | |
CA2813268A1 | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions | |
BRPI0216033B1 | "peptide-based immunization therapy for treatment of arteriosclerosis" |